Metronidazole Extended-Release Formulation in the Management of Multidrug-Resistant Infections: Efficacy, Mechanisms, and Therapeutic Synergy with Current Treatment Options

Multidrug-resistant (MDR) infections are becoming more prevalent, which presents serious problems for global healthcareand calls for creative approaches to treatment as well as a reassessment of current medications. Because of its stronganaerobic and protozoal action, Metronidazole extended-release formulation has demonstrated promise in treating variousMDR illnesses. The function of Metronidazole extended-release formulation in treating MDR infections is examined invarious studies, with a focus on anaerobic bacteria that are frequently present in soft-tissue, pelvic, and intra-abdominalinfections. The prolonged-release formulation has advantages, such as sustained therapeutic levels and a decreased dosingfrequency, which may improve patient adherence and clinical outcomes, even though it is effective in treating diseases likebacterial vaginosis, Clostridium difficile infections, etc. This study addresses existing limitations and offers insights intoimproving treatment for MDR infections by contrasting Metronidazole extended-release formulation with alternative andcomplementary medicines, including glycopeptides, carbapenems, and combination regimens. Although Metronidazoleextended-release formulation is still a useful treatment option for MDR infections, its effectiveness is best complementedby a multidrug strategy that is customized to the complexity and resistance profile of the illness.